1008-65-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(1,3,4-OXADIAZOL-2-YL)PHENOL is used as a building block for creating new drugs, leveraging its chemical properties to target a range of diseases and conditions. Its heterocyclic nature allows for the development of compounds with specific therapeutic effects.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 2-(1,3,4-OXADIAZOL-2-YL)PHENOL is used as an active agent for its potential to combat various microorganisms, contributing to the development of new antimicrobial drugs.
Used in Antifungal Applications:
Similarly, in antifungal applications, 2-(1,3,4-OXADIAZOL-2-YL)PHENOL is utilized for its ability to inhibit fungal growth, making it a candidate for the creation of antifungal medications.
Used in Antioxidant Applications:
2-(1,3,4-OXADIAZOL-2-YL)PHENOL is used as an antioxidant, capitalizing on its potential to neutralize free radicals and thereby offering protective effects against oxidative stress-related conditions.
Used in Anticancer Applications:
In oncology, 2-(1,3,4-OXADIAZOL-2-YL)PHENOL is studied for its potential as an anticancer agent, with research focusing on its ability to interfere with cancer cell growth and proliferation.
Used in Academic and Industrial Research:
2-(1,3,4-OXADIAZOL-2-YL)PHENOL is used in research studies across academia and industry due to its unique chemical structure, which presents opportunities for exploration in biotechnology and materials science.
Used in Biotechnology:
Within the biotechnology sector, 2-(1,3,4-OXADIAZOL-2-YL)PHENOL is employed for its potential applications in the development of new technologies, including biosensors and other bioanalytical tools.
Used in Materials Science:
In materials science, 2-(1,3,4-OXADIAZOL-2-YL)PHENOL is utilized for its possible contributions to the creation of novel materials with specific properties, such as those with enhanced stability or reactivity.

InChI:InChI=1/C8H6N2O2/c11-7-4-2-1-3-6(7)8-10-9-5-12-8/h1-5,10H

Upstream product

• 936-02-7 2-Hydroxybenzoylhydrazine 
• 122-51-0 orthoformic acid triethyl ester 
• 75-52-5 nitromethane 
• 1010-85-1 N'-formyl-2-hydroxybenzohydrazide 
• 119-36-8 methyl salicylate 
• 70203-02-0 N'-(2-phenyl-2-ethylidene)-2-hydroxybenzohydrazide 
• 579-75-9 2-Methoxybenzoic acid 
• 2476-35-9 5-bromo-2-methoxybenzoic acid 
• 42966-95-0 2-(2-methoxyphenyl)-1,3,4-oxadiazole 
• 7466-54-8 2-methoxybenzoylhydrazine 

Downstream Products

• 13584-11-7 4-[2-(2-[1,3,4]oxadiazol-2-yl-phenoxy)-ethyl]-morpholine 
• 13584-23-1 carbonic acid bis-(2-[1,3,4]oxadiazol-2-yl-phenyl) ester 
• 13584-06-0 2-(2-pentyloxy-phenyl)-[1,3,4]oxadiazole 
• 13583-97-6 1-ethoxycarbonyloxy-2-[1,3,4]oxadiazol-2-yl-benzene 
• 13584-22-0 1-acetoxy-2-[1,3,4]oxadiazol-2-yl-benzene 
• 13584-04-8 2-(2-ethoxy-phenyl)-[1,3,4]oxadiazole 
• 13584-05-9 2-(2-propoxy-phenyl)-[1,3,4]oxadiazole 
• 13584-12-8 (2-[1,3,4]oxadiazol-2-yl-phenoxy)-acetic acid ethyl ester 
• 92043-41-9 dimethyl-[2-(2-[1,3,4]oxadiazol-2-yl-phenoxy)-propyl]-amine 
• 13584-10-6 diethyl-[2-(2-[1,3,4]oxadiazol-2-yl-phenoxy)-ethyl]-amine 
• 13584-08-2 2-(2-allyloxy-phenyl)-[1,3,4]oxadiazole 
• 13584-09-3 2-(2-prop-2-ynyloxy-phenyl)-[1,3,4]oxadiazole 
• 13584-18-4 (2-[1,3,4]oxadiazol-2-yl-phenoxy)-phenyl-acetic acid ethyl ester 
• 13584-17-3 2-(2-[1,3,4]oxadiazol-2-yl-phenoxy)-propionamide 

Relevant academic research and scientific papers

Electrophilic activation of nitroalkanes in efficient synthesis of 1,3,4-oxadiazoles

A novel methodology for general and chemoselective preparation of non-symmetric 1,3,4-oxadiazoles is developed. This unusual reaction proceeds via polyphosphoric acid-assisted activation of nitroalkanes towards nucleophilic attack with acylhydrazides.

Spectral-Luminescent Properties of 2-Aryl-1,3,4-oxadiazoles

Refluxing equimolar amounts of acylhydrazides with triethyl orthoformate in o-xylene yielded 2-aryl-1,3,4-oxadiazoles luminescing with high quantum yields in polar and nonpolar solvents (λm fl ax 299–349 nm, φ 0.20–0.62). The only exception was 2-(1,3,4-o

Synthesis and Biological Evaluation of Some Heterocyclic Compounds from Salicylic Acid Hydrazide

Different heterocyclic compounds were prepared starting from 2-hydroxy benzohydrazide; for example, cyclization of hydrazide hydrazone 3 derived from 2-hydroxybenzohydrazide 2 with acetic anhydride or concentrated sulfuric acid gave 1,3,4-oxadiazole derivatives 4–5. On the other hand, direct cyclization of 2-hydroxy benzohydrazide 2 with one carbon cyclizing agent gave a new derivative of 1,3,4-oxadiazole 7, 8, 9, 10, 11. Heating of hydrazide hydrazone 3 with thioglycolic acid in pyridine gave thiazolidinone 12. When 2-hydroxy benzohydrazide 2 reacted with aliphatic carboxylic acids such as formic acid or acetic acid, it gave the corresponding N-formyl or N-acetyl derivatives 6. Subsequent cyclization of 6 using phosphorous pentasulphide in pyridine gave 1,3,4-thiadiazoles 13. Cyclization of 2-hydroxy benzohydrazide with ethyl acetoacetate gives pyrazolone derivative 14. Finally, when an ethanolic solution of acid hydrazide 2 was treated with ammonium thiocyanate in 35% HCl, it gave the thiosemicarbazide 15. Subsequent treatment of 15 with concentrated sulfuric acid or 10% sodium hydroxide gave 5-amino-1,3,4-thiadiazole 16 and 1,2,4-triazole 17, respectively. The structures of all newly isolated compounds were confirmed using1H NMR, IR spectra, and elemental analyses. The antimicrobial activities for all isolated compounds were examined against different microorganisms.

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

Compounds enhancing antitumor activity of other cytotoxic agents

This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).